Last reviewed · How we verify
Fang yi qing feng shi granule
Fang yi qing feng shi granule is a Small molecule drug developed by Maoxiang Group Jilin Pharmaceutical Co., Ltd.. It is currently in Phase 2 development.
At a glance
| Generic name | Fang yi qing feng shi granule |
|---|---|
| Sponsor | Maoxiang Group Jilin Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of Fang yi Qing Feng Shi Granules in Subjects With Rheumatoid Arthritis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fang yi qing feng shi granule CI brief — competitive landscape report
- Fang yi qing feng shi granule updates RSS · CI watch RSS
- Maoxiang Group Jilin Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about Fang yi qing feng shi granule
What is Fang yi qing feng shi granule?
Fang yi qing feng shi granule is a Small molecule drug developed by Maoxiang Group Jilin Pharmaceutical Co., Ltd..
Who makes Fang yi qing feng shi granule?
Fang yi qing feng shi granule is developed by Maoxiang Group Jilin Pharmaceutical Co., Ltd. (see full Maoxiang Group Jilin Pharmaceutical Co., Ltd. pipeline at /company/maoxiang-group-jilin-pharmaceutical-co-ltd).
What development phase is Fang yi qing feng shi granule in?
Fang yi qing feng shi granule is in Phase 2.